Eton Pharmaceuticals (ETON) Cash & Equivalents (2017 - 2025)

Eton Pharmaceuticals (ETON) has 9 years of Cash & Equivalents data on file, last reported at $25.9 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 73.69% year-over-year to $25.9 million; the trailing twelve-month figure through Dec 2025 stood at $25.9 million (up 73.69% YoY), and the FY2025 full-year result was $25.9 million, up 73.69% from the prior year.
• Cash & Equivalents eased to $25.9 million in Q4 2025, from $37.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $37.1 million in Q3 2025 to a low of $13.4 million in Q3 2022.
• A 5-year average of $20.3 million and a median of $19.0 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents surged 209.72% in 2021 and slumped 41.09% in 2022, its largest moves.
• Tracing ETON's Cash & Equivalents over 5 years: stood at $14.4 million in 2021, then climbed by 13.18% to $16.3 million in 2022, then jumped by 31.17% to $21.4 million in 2023, then tumbled by 30.17% to $14.9 million in 2024, then soared by 73.69% to $25.9 million in 2025.
• Business Quant data shows ETON's Cash & Equivalents at $25.9 million in Q4 2025, $37.1 million in Q3 2025, and $25.4 million in Q2 2025.